T-cell responses can be antagonized by some single amino acid-substituted analogs of a peptide ligand for T-cell receptors (TCR), and these are called TCR antagonists. In this study, we addressed the question of whether TCR antagonism can be elicited by a whole protein antigen carrying a mutated T-cell determinant region corresponding to a TCR antagonist peptide. To clarify this, we examined the ability of a single amino acid-substituted mutant form of bovine -lactoglobulin (-Lg) to inhibit three CD4 + T-cell clones recognizing a peptide corresponding to an immunodominant determinant region 119-133 of -Lg (p119-133). First, we identified pD129A, an analog of p119-133 with a substitution of Ala for 129 Asp, as an antagonist which can inhibit the response of two of the three T-cell clones. Then, using a yeast expression system, we prepared a mutant -Lg (mutD129A) with the same substitution of Ala for 129 Asp as that in pD129A. This mutant protein could inhibit the proliferation of the two T-cell clones in a manner similar to the effect of pD129A. From these results we can demonstrate that TCR antagonism can be elicited by peptides naturally processed from a single-substituted mutant protein as well as by the corresponding peptides added exogenously.
Introduction
T cells are activated after recognizing peptide fragments in the form of a complex with a major histocompatibility complex (MHC) molecule, via their surface antigen receptors (T-cell receptor; TCR). Recent studies have revealed that T-cell responses are altered by stimulation with analogs of peptide ligands for their TCRs, which are called altered peptide ligands (SloanLancaster and Allen, 1996; Kersh and Allen, 1996) . Altered peptide ligands partially activate the T cells of both CD4 + (Evavold and Allen, 1991; Evavold et al., 1993; Sloan et al., 1993; Racioppi et al., 1993; Sloan et al., 1994) and CD8 + (Cao et al., 1995) phenotypes, or induce antigen-specific inhibition of T-cell responses, a phenomenon called TCR antagonism (De Magistris et al., 1992) . By analogy with the concept of antagonism in pharmacology, a TCR antagonist peptide in complex with a MHC molecule was originally considered to competitively bind to TCR without inducing any signals (De Magistris et al., 1992) . This hypothesis was challenged by the evidence that antagonist peptides induce a partial phosphorylation of CD3 chains, which play a key role in the signaling through TCR (Reis e Sousa et al., 1996; La Face et al., 1997) . Two hypotheses have been proposed for operative mechanisms of partial activation and TCR antagonism; the kinetic model that a different response results from quantitatively less interaction between TCR and an altered peptide ligand than that between TCR and an agonist ligand (Jameson and Bevan, 1995; McKeithan, 1995) , and the conformational model that TCR signal transduction involves some type of conformational change and this change is qualitatively different when the TCR recognizes an altered peptide ligand as compared to an agonist (Janeway, 1995) . Although there have been several reports supporting either of these models (Lyons et al., 1996; Yoon et al., 1994) , the molecular mechanisms underlying TCR antagonism are not yet fully clarified.
There have been several reports implying that TCR antagonism may be of physiological importance. TCR antagonist peptides added to a thymus organ culture can positively and/or negatively select T cells, suggesting that thymic selection of T cells is influenced by self peptides functioning as TCR antagonists (Hogquist et al., 1994; Ashton-Rickardt et al., 1994) . The in vivo effects of TCR antagonists have also been demonstrated with respect to inhibition of the onset of several experimental autoimmune diseases caused by pathogenic T-cell responses, such as experimental allergic encephalomyelitis (Kuchroo et al., 1994; Karin et al., 1994; Nicholson et al., 1997) and experimental autoimmune uveitis (Singh et al., 1994) . In infections by some viruses, naturally occurring variants of the determinants recognized by CD8 + cytotoxic T cells may act as antagonists in vivo to avoid recognition and elimination by host T cells, because the corresponding peptides specifically prevent the T-cell response directed against the virus in vitro (Allen and Zinkernagel, 1994; Klenerman et al., 1994; Bertoletti et al., 1994) . It is important to note that these variant determinants, which are restricted to MHC class I molecules, can act as antagonists not only in the form of exogenous peptides but also when expressed as proteins endogenously by recombinant viruses. However, as for class IIrestricted T-cell responses, TCR antagonism has been demonstrated only using exogenously added peptides. Therefore, it is not obvious whether mutant proteins incorporated or generated in the organism may function as TCR antagonists for CD4 + T cells, because (i) antigen processing pathways involving class I and class II MHC molecules are totally different from each other (reviewed in Germain and Margulies, 1993) and (ii) peptide and protein antigens reportedly require distinct antigen-presenting cell (APC) subsets for the priming of CD4 + T cells (Constant et al., 1995) . Considering that natural immune responses in vivo are elicited primarily by protein antigens and not by peptides, it is worth examining whether mutant proteins with a single substitution can antagonize specific CD4 + T cells.
In the present study, we investigated the TCR antagonistic activity of a mutant protein using a panel of T-cell clones specific for region 119-133 of bovinelactoglobulin (-Lg), a major allergen in cow's milk (Taylor, 1986) . Single-substituted analogs of peptide 119-133 (p119-133) were prepared and examined for their TCR antagonist activity. pD129A, an analog of p119-133 with a substitution of Ala for residue 129 Asp, was shown to have a TCR antagonistic activity for the p119-133-specific clones. A mutant of -Lg with the same substitution as that in pD129A produced using a yeast expression system (Totsuka et al., 1990; Katakura et al., 1994) inhibited the proliferative responses of these clones in an antigen-specific manner. Our data demonstrate that TCR antagonism can be elicited by mutant proteins with a single substitution, and suggest the natural occurrence of TCR antagonism mediated by mutant proteins generated in vivo by a genetic mutation.
Materials and methods

Animals
C57BL/6 (B6) mice (H-2 b : female, 8-week old) were purchased from Charles River Japan Inc. (Yokohama, Japan).
Proteins and peptides
Bovine -lactoglobulin (-Lg; genetic variant A) was prepared from raw milk of a cow of the genotype AA for -Lg as described previously (Kaminogawa et al., 1989) . Reduced and carboxymethylated (RCM) -Lg was prepared by carboxymethylation of reduced -Lg according to the method of McKenzie (McKenzie et al., 1972) . A peptide corresponding to region 119-133 in bovine -Lg (p119-133; CQCLVRTPEVDDEAL), its analog peptide having a substitution of Ala for 129 Asp, pD129A, and a peptide corresponding to region 136-155 of bovine s1 -casein (P10; IGVNQELAYFYPEL-FRQFYQ) were synthesized using a peptide synthesizer (Model 430A; Perkin-Elmer, Norwalk, CT, U. S. A.) and purified by reversed-phase HPLC. Singlesubstituted analogs of p119-133 used for identifying TCR antagonists (Table 1) were purchased from Chiron Mimotopes (Clayton, Australia). 
a Dashes indicate identity with the p119-133 sequence.
T-cell clones
CD4 + T-cell clones specific for -Lg, G1.19, F2.8, and F12.5, were established as described elsewhere (submitted for publication). Briefly, B6 mice were immunized subcutaneously with bovine -Lg emulsified with CFA-H37Ra. Lymph-node cells prepared from the mice 7 days after immunization were stimulated every week with 5 M -Lg, and 10% T-cell growth factor (TCGF; supernatant from ConA-activated rat splenocytes) prepared as described previously (Rosenberg et al., 1978) , in the presence of 3000-rad irradiated syngeneic splenocytes as antigen-presenting cells (APCs). The medium used for the cell culture was RPMI1640 medium supplemented with 10% fetal calf serum (FCS), 50 M 2-mercaptoethanol, 100 U/ml penicillin, and 100 g/ml streptomycin. After a fourmonth culture period, the cells were cloned by the limiting dilution method. The cloned cells were stimulated with 2.5 M -Lg, 10% TCGF and irradiated syngeneic splenocytes once a week for 4-5 months. The resulting T-cell clones, G1.19, F2.8, and F12.5, were established from different T-cell lines each derived from different mice. The characteristics of the T-cell clones used in this study are summarized in 
Pre-pulse assay for identifying T-cell receptor antagonist peptides
Irradiated syngeneic splenocytes as APC were incubated with a suboptimal concentration of p119-133 (0.3 M) for 2 h at 37 C (pre-pulse). After removal of the unbound peptides by washing, the antigenpulsed cells were cultured in 96-well plates at 2 10 5 cells/well with cloned T cells (4 10 4 cells/well) and varying concentrations of the analog peptides. Proliferation of the cells was measured as described above.
Construction of the expression plasmid for a mutant
-Lg
Bovine -Lg cDNA isolation and expression in yeast were described previously (Totsuka et al., 1990) . To facilitate construction of an expression plasmid in yeast, a Sac I/Sma I fragment of -Lg cDNA containing the whole coding region was ligated with a Sal I linker at each end, and inserted into the Sal I site of pUC118. Then, the cDNA fragment was modified in the region around the initiation codon to give the sequence, 5 0 -CTAAAAAAATGAAG-3 0 , instead of 5 0 -CTGCAGCCATGAAG-3 0 , and the resulting plasmid was designated pBAML. This upstream sequence is common to mRNAs for proteins expressed at high levels in yeast, and is expected to increase the expression level in yeast (Hamilton et al., 1987) .
Site-directed mutagenesis of the coding region of -Lg cDNA was performed by means of the polymerase chain reaction (PCR). To introduce a mutation resulting in the substitution of Ala for 129 Asp, two mutagenic oligonucleotide primers, D129A-back primer (5 0 -CCCCGGAGGTGGCTGACGAGGCCCTG- 3 0 ) and D129A-forward primer (5 0 -CAGGGCCTCGT-CAGCCACCTCCGGGG-3 0 ) were used as well as M13-universal primer (5 0 -GTAAAACGACGGCCAGT-3 0 ) and M13-reverse primer (5 0 -CAGGAAACAGCTA-TGAC-3 0 ). These primers were synthesized with a DNA synthesizer (Model Cyclone Plus; Millipore, Bedford, MA, U.S.A.). For the first round of PCR amplification, a set of the D129A-back primer and the M13-universal primer (for PCR-A), or a set of the D129A-forward primer and the M13-reverse primer (for PCR-B) was used. A 50-l reaction mixture was prepared containing 10 mM Tris-HCl (pH 8.0), 50 mM KCl, 1.5 mM MgCl 2 , 0.1% Triton X-100, 10 pmol of each primer, 0.1 pmol of pYBAML as template DNAs, 250 M dNTP and 0.5 U of Taq DNA polymerase and then overlaid with mineral oil. The reaction was allowed to proceed for 30 cycles (30 s, 94 C; 20 s, 55 C; 2 min, 72 C). The second PCR amplification was performed with the M13-universal primer and the M13-reverse primer in a 50-l mixture containing 3 l each of the products of PCR-A and PCR-B. After fractionating the reaction products according to size on a 1.5% agarose gel, the appropriate band was excised and purified using a Gene Clean Kit II (Bio 101, La Jolla, CA, U.S.A.). The PCR product was digested with Sal I and ligated into pUC118. The sequence of the PCR product was confirmed by DNA sequencing using a PRISM kit (Perkin-Elmer) and a DNA sequencer (Model 370A; Perkin-Elmer). The Sal I fragment of the mutated -Lg cDNA was excised and ligated into the Sal I site of pYG100, an expression plasmid vector for yeast (Kumagai and Miura, 1989) . The resulting plasmid for expression of the mutant -Lg was designated pYD129A.
Expression and purification of recombinant proteins
The expression plasmid, pYD129A, was introduced into Saccharomyces cerevisiae strain AH22 (Mat a, can1 ) by the lithium acetate method (Ito et al., 1983) . Yeast culture and purification of recombinant proteins from the yeastculture supernatant were performed as described previously (Katakura et al., 1994; Katakura et al., 1997) . Briefly, transformed yeast cells were grown at 30 C for 4 days in a modified synthetic minimal medium (Ichikawa et al., 1989) . The culture supernatant was concentrated 160-fold by ultrafiltration and diluted eight-fold with 0.05 M imidazole-HCl buffer (pH 6.7). Proteins in the concentrated sample were purified by sequential chromatography on a DEAESephacel column (Pharmacia Biotech, Uppsala, Sweden) and a Superose 12 gel-filtration column (Pharmacia Biotech). At each purification step, mutant -Lgs were detected by sandwich ELISA using anti--Lg mAb 62A6 and alkaline phosphatase-labeled anti--Lg mAb 61C1 as described previously (Totsuka et al., 1990) .
SDS-polyacrylamide gel electrophoresis
An SDS-polyacrylamide gel containing 15% acrylamide was used as the running gel and electrophoresis was performed under reducing conditions by the method of Laemmli (Laemmli, 1970) . Gels were stained with Coomassie Brilliant Blue R-250.
Competitive enzyme linked immuno-sorbent assay (ELISA)
To examine the conformational integrity of purified mutD129A, competitive ELISA was performed using anti-bovine -Lg monoclonal antibodies (mAbs) as probes, as employed in our previous studies (Kaminogawa et al., 1989; Hattori et al., 1993; Katakura et al., 1994) . Anti--Lg mAbs from the B-cell hybridoma clones 21B3, 31A4, and 61C1 were purified from ascites as described previously (Kaminogawa et al., 1989 
Results
Identification of a TCR antagonist peptide effective for p119-133-specific T-cell clones
In our previous study, we identified an immunodominant T-cell determinant of bovine -Lg in region 119-133 using B6 mice and revealed that residues of region 122-130 are essential for the determinant to be recognized by T cells (Totsuka et al., in press ). Further, residues 126 Pro and 128 Val were identified to play a critical role for p119-133 to bind to MHC class II I-A b molecules from B6 mice (manuscript in preparation). From these findings, we assumed that among the residues in the region 122-130 other than 126 Pro and 128 Val there are critical TCR contacting residues and we prepared a series of single-substituted peptides of p119-133 with a substitution at each of these residues (Table 1) , since most of TCR antagonist peptides previously identified have a substitution at a TCR contacting residue. First, we examined the ability of the analog peptides to induce proliferation of G1.19, a CD4 + Tcell clone specific for p119-133 (Table 2) , because a TCR antagonist induces no proliferation of relevant T cells by itself (De Magistris et al., 1992) . As shown in Figure 1 , pL122D, pV123D, pT125A, and pD130A at 50 M each elicited a positive response (stimulation index > 2) in the proliferation assay using G1.19 cells.
These peptides were not tested further in an antagonist assay.
Next, we examined whether pR124A, pE127A, and pD129A which induced no response of G1.19 were effective to inhibit the proliferative response of G1.19 to p119-133 (Figure 2 ). To avoid competition between the analog peptide and p119-133 in binding to I-A b molecules, APCs were incubated with p119-133 prior to the incubation with G1.19 cells and the analog peptide. In preliminary experiments, G1.19 showed a proliferative response to APC that had been previously incubated with p119-133 at concentrations of 0.1 M or more, and the intensity of the response was dependent on the dose of p119-133 at the time of pre-incubation (data not shown). Based on these findings, we chose to employ 0.3 M as the concentration of p119-133 for the pre-incubation, at which a suboptimal but significant proliferative response of G1.19 was induced. As shown in Figure 2 , only pD129A inhibited the proliferative response of G1.19 to p119-133. The response of G1.19 was not inhibited in the presence of a control peptide, P10, which is known to bind to I-A b molecules and contains a determinant of bovine s1 -casein recognized as an immunodominant T-cell determinant in B6 mice (unpublished observation). We next examined the ability of pD129A to function as a TCR antagonist for two other p119-133-specific clones, F2.8 and F12.5 ( Table 2) . As shown in Figure 3 , the proliferative response of F12.5 to p119-133-pre-pulsed APC was inhibited by pD129A as well as that of G1.19, confirming the TCR antagonist activity of pD129A for this clone. However, pD129A enhanced the proliferation of F2.8, demonstrating that F2.8 recognizes pD129A as an agonist. In these experiments, P10 added to the culture instead of pD129A did not inhibit the responses (data not shown).
Preparation of mutD129A, a mutant -Lg with the same substitution as that in pD129A which is a TCR antagonist for p119-133-specific T-cell clones
We prepared a mutant of -Lg with the same single substitution as that in pD129A using the yeast expression system previously established (Totsuka et al., 1990) .
The mutated -Lg cDNA fragment was expressed in yeast under control of the promoter and terminator of the yeast glyceraldehyde triphosphate dehydrogenase gene in the yeast expression plasmid pYG100 (Kumagai and Miura, 1989). The mutant protein was secreted into the culture medium, from which the recombinant protein was purified by two sequential steps of column chromatography (Katakura et al., 1997) . The purified protein was subjected to SDS-polyacrylamide gel electrophoresis (SDS-PAGE) and stained with Coomassie Brilliant Blue. As shown in Figure 4 , mutD129A was purified to more than 90% purity and showed the same mobility as -Lg.
To examine the conformational integrity of the recombinant protein, competitive ELISA was performed using anti--Lg mAbs, 21B3, 31A4 and 61C1, which were shown to be useful as probes for examining conformational changes occurring in -Lg (Kaminogawa et al., 1989; Hattori et al., 1993; Katakura et al., 1994) . Other anti--Lg mAbs employed in previous studies, 62A6 and 61B4, that recognize the region 125-135 (Kaminogawa et al., 1989) , could not be used for evaluating the conformation of mutD129A, because the reactivity of these mAbs was impaired by the substitution at residue 129 Asp (data not shown). In contrast, the mAbs used in this study recognize regions irrelevant to the substitution (Kaminogawa et al., 1989) , and thus are not considered to be affected directly by the difference in amino acid sequence between the mutant and the wild-type. We compared the binding curves of each mAb to native -Lg immobilized in plate wells in the presence of various concentrations of competitive antigen added together with mAbs in the aqueous phase. Reduced and carboxymethylated (RCM) -Lg was used as a denatured--Lg control. As shown in Figure 5 , anti--Lg mAbs 21B3 and 31A4, recognizing regions 15-29 and 8-19 of -Lg (Kaminogawa et al., 1989) , respectively, bind to mutD129A with almost the same binding affinities as those to native -Lg. mAb 61C1 which is specific for region 15-29 (Kaminogawa Figure 4 . SDS-polyacrylamide gel electrophoresis pattern of the purified mutD129A. SDS-PAGE was performed using a 15% gel according to the method of Laemmli (Laemmli, 1970) , and subsequently subjected to staining with Coomassie Brilliant Blue. Lane 1; molecular weight markers (from top, bovine serum albumin, ovalbumin, and hen egg-white lysozyme), lane 2; purified mutD129A (10 g), lane 3; native -Lg (10 g).
et al., 1989) showed almost the same binding curves for native -Lg and mutD129A, although the difference in its binding to native -Lg and RCM -Lg is not so obvious. These results suggest that mutD129A retains almost the same overall conformation as that of native -Lg.
TCR antagonist activity of mutD129A
To examine whether a mutant protein can mediate TCR antagonism, we examined the ability of mutD129A to inhibit the proliferative responses of the p119-133-specific T-cell clones. The T-cell clones, G1.19, F2.8 and F12.5, were cultured with native -Lg at 0.3 m and various concentrations of mutD129A in the presence of APCs. As shown in Figure 6 , the proliferation of G1.19 and F12.5, for which pD129A functions as a TCR antagonist, were inhibited in a dose-dependent manner by mutD129A added to the culture. It is worth noting that 1 M mutD129A, a dose only about threefold that of native -Lg, could inhibit the proliferative response of F12.5 cells by 50%. In contrast, F2.8 showed increased proliferation in the presence of mutD129A. These results indicate that the inhibition of T-cell responses by mutD129A is antigen-specific, and demonstrate that TCR antagonism for CD4 + T cells can be mediated by mutant proteins.
Discussion
In the present study, we identified a TCR antagonist peptide effective for CD4 + T-cell clones, and demonstrate that a mutant form of a protein antigen with the same single substitution as the TCR antagonist peptide can inhibit the activation of the CD4 + T-cell clones displayed in response to the wild-type protein. This illustrates that TCR antagonism of class II MHC-restricted CD4 + T cells can be mediated by peptides naturally processed from a mutant protein as well as by the corresponding peptides added extracellularly. It is of importance to note that a point mutation can provide a protein with a potent TCR antagonist activity. Some of the variants of a protein antigen resulting from genetic mutations may be able to mediate TCR antagonism in vivo. This is comparable with the finding that class I MHC-restricted CD8 + T cells can be inhibited by antagonist epitopes expressed as proteins endogenously by variant viruses (Allen and Zinkernagel, 1994; Klenerman et al., 1994; Bertoletti et al., 1994) . Antagonistic activity by these protein antigens may explain the mechanisms of self tolerance, the poor immune response to tumor cells, and the escape of infectious microbes and viruses from immune surveillance.
We employed three -Lg-specific CD4 + T-cell clones (Table 2 ) each recognizing the same single peptide, p119-133, to evaluate the inhibitory effect of mutD129A prepared from the yeast culture supernatant. T-cell clones G1.19 and F12.5 were inhibited by pD129A through TCR antagonism (Figure 3) . In contrast, the TCR of F2.8 cells recognized pD129A as an agonist and the proliferative response of this clone was increased by the addition of pD129A. Similarly, mutD129A having the same substitution as pD129A inhibited both G1.19 and F12.5 but not F2.8, indicating the same specificity of inhibition as pD129A (Figure 6) . The inhibition by mutD129A is not likely due to nonspecific inhibitors which may be included as impurities in the preparation of the mutant protein, because F2.8 cells showed strong proliferation in the presence of mutD129A at 10 m which inhibited almost completely the proliferation of G1.19 and F12.5 cells.
As shown above, pD129A and mutD129A could not inhibit all T-cell clones specific for p119-133. Analog peptides acting as TCR antagonists reportedly differ in effectiveness towards T-cell clones specific for the same determinant, as recognition is probably dependent on TCR sequences. When we consider the practical application of TCR antagonists to inhibit deleterious T-cell responses, it is not necessary to employ a TCR antagonist that can inhibit all specific T cells. A TCR antagonist with the ability to inhibit most of the relevant T cells may effectively inhibit T cell responses in vivo. In fact, a single TCR antagonist peptide could efficiently inhibit experimental autoimmune diseases mediated by a diverse T-cell repertoire (Kuchroo et al., 1994; Singh et al., 1994) . A MHC class II molecule has a peptide-binding groove that is open at each end (Brown et al., 1993; Stern et al., 1994) . Therefore, it is possible that a denatured protein molecule with a long extended shape binds to a MHC class II molecule (Sette et al., 1989; Lee et al., 1988) . Moreover, denatured protein molecules may be susceptible to attack by enzymatic digestion in the culture supernatant of T cells, resulting in the formation of peptide fragments which can bind to MHC class II molecules displayed on APC. If mutD129A has a denatured conformation, these possibilities should be considered in evaluating the inhibitory effect of the mutant protein. From the results of binding analyses using our set of mAbs ( Figure 5) , we can rationally demonstrate that mutD129A has an overall conformation almost equal to that of native -Lg. Therefore, mutD129A can be considered to be processed in APC and displayed on MHC molecules in the same way as native -Lg, excluding the possibilities mentioned above.
The possibility that competitive exchange occurs between antigenic peptides bound to MHC class II molecules and TCR antagonist peptides cannot be completely excluded even in the pre-pulse assay where antigenic peptides were incubated with APC in advance to decrease the competition to as little as possible. The finding that mutD129A has TCR antagonist activity clearly shows that the competition between peptides for MHC binding at the cell surface is totally irrelevant to TCR antagonism, because mutD129A needs to be processed in APC in order to exhibit this activity. Moreover, competition for binding to class II MHC molecules in endocytic vesicles between peptides derived from proteins added extracellularly is not likely to influence the T-cell response, considering that the corresponding doses of hen egg-white lysozyme added to the culture instead of mutD129A showed no effect on proliferation of the T cells (data not shown). Thus, inhibition of T-cell response by mutD129A was mediated by TCR antagonism, and not by antigenic competition.
mutD129A inhibited 50% of the response of F12.5 cells at 1 M, approximately a 3-fold higher concentration than that of -Lg added to the culture, and mutD129A almost completely inhibited the response at 10 M (Figure 6 ). G1.19 was also inhibited thoroughly by mutD129A at 10 M. In the pre-pulse assay, pD129A at 10 M showed only 30 to 50% inhibition of the proliferative response of G1.19 or F12.5 cells to APC pre-incubated with p119-133 at 0.3 M (Figure 3) . The same results were obtained in an assay where p119-133 and pD129A were added to the culture simultaneously (data not shown). It is possible that mutD129A is more efficient than pD129A in inhibiting the response of the T-cell clones specific for p119-133, although it cannot be definitely ascertained from only these results. Legge et al. have recently shown that immunoglobulin (Ig) molecules displaying the sequence of a proteolipidprotein (PLP) TCR antagonist peptide can abrogate more effectively than the peptide antagonist the activation of T cells stimulated with the original PLP peptide (Legge et al., 1997) . They attributed the effectiveness of the Ig antagonist to its efficient endocytic processing leading to the generation of TCR antagonist peptides. In a situation in which immune responses have already been elicited by a protein antigen in vivo, a TCR antagonist mutant form of the protein with a single substitution may have greater potential for inhibiting the T-cell responses as compared to an analog peptide with the same substitution. B cells can present peptides from a protein that can bind to their surface immunoglobulin 10 4 times more efficiently than those from non-specific proteins (Lanzavecchia, 1985) . A protein molecule bound by specific antibodies is also efficiently captured by APC through their surface Fc receptors and presented to T cells. When immune responses to a protein antigen have been established, a larger number of B cells and antibodies bind specifically to a mutant form of that protein than to an analog peptide which is only a fragment of the mutant protein. Therefore, the antagonistic mutant protein is considered to be presented more effectively as compared to the analog peptides, resulting in more potent inhibition of T-cell activation. In addition, a mutant protein may have a longer half-life in vivo than an analog peptide because of its higher resistance to enzymatic digestion. The use of artificial genes encoding a mutant TCR antagonist protein to be expressed in vivo may be applicable as a means of gene therapy for abrogating pathogenic T-cell responses and ameliorating T-cell mediated autoimmune diseases, such as multiple sclerosis, type I diabetes, and rheumatoid arthritis.
